"Hypertension increases the risk of cardiovascular disease and accelerates the development of atherosclerosis. The risk of cardiovascular disease in hypertensive patients can significantly reduce the effective antihypertensive therapy. Currently, patients with ischemic heart disease (CHD) to achieve recommended target blood pressure 130-139/80-85 mm Hg. Drugs of choice for hypertension accompanied by angina and in patients after myocardial infarction, beta-blockers. Cardioselective beta-blockers are also clearly indicated in diabetic patients with coronary heart disease. Some beta-blockers (carvedilol, bisoprolol, metoprolol, and nebivolol ZOK) improve the prognosis of patients with chronic heart failure. Alternatively, normal left ventricular function (especially when counter-indication or intolerance of beta-blockers) used verapamil or diltiazem. When persistent anginal symptomatology is advantageous to add beta-blockers calcium channel blockers of the dihydropyridine group second generation. In hypertensive patients with coronary artery disease and left ventricular systolic dysfunction, ACE inhibitors are indicated, possibly. AT1-receptor blockers, angiotensin II (AT1-blockers). They should be considered even in patients with coronary artery disease and normal left ventricular function. (Ch cardiology 2011; 3: 59-63)"@en . . . . "RIV/00064190:_____/11:#0000285" . "3" . . "2" . "Hypertenze a ischemick\u00E1 choroba srde\u010Dn\u00ED" . . "5"^^ . . . . . "Hypertenze a ischemick\u00E1 choroba srde\u010Dn\u00ED"@cs . "Hypertenze a ischemick\u00E1 choroba srde\u010Dn\u00ED" . . "Hypertenze a ischemick\u00E1 choroba srde\u010Dn\u00ED"@cs . "1"^^ . "N" . "Hypertenze zvy\u0161uje riziko kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED a akceleruje rozvoj ateroskler\u00F3zy. Riziko kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED u hypertonik\u016F lze v\u00FDznamn\u011B sn\u00ED\u017Eit \u00FA\u010Dinnou antihypertenzn\u00ED l\u00E9\u010Dbou. V sou\u010Dasn\u00E9 dob\u011B je u pacient\u016F s ischemickou chorobou srde\u010Dn\u00ED (ICHS) doporu\u010Dov\u00E1no dos\u00E1hnout c\u00EDlov\u00FDch hodnot krevn\u00EDho tlaku 130\u2013139/80\u201385 mm Hg. L\u00E9ky volby u hypertenze prov\u00E1zen\u00E9 anginou pectoris a u nemocn\u00FDch po infarktu myokardu jsou beta-blok\u00E1tory. Kardioselektivn\u00ED beta-blok\u00E1tory jsou jednozna\u010Dn\u011B indikov\u00E1ny tak\u00E9 u diabetik\u016F s ICHS. N\u011Bkter\u00E9 beta-blok\u00E1tory (carvedilol, bisoprolol, metoprolol ZOK a nebivolol) zlep\u0161uj\u00ED progn\u00F3zu nemocn\u00FDch s chronick\u00FDm srde\u010Dn\u00EDm selh\u00E1n\u00EDm. Alternativn\u011B lze p\u0159i norm\u00E1ln\u00ED funkci lev\u00E9 komory (zvl\u00E1\u0161t\u011B p\u0159i kontra indikaci nebo intoleranci beta-blok\u00E1tor\u016F) u\u017E\u00EDt verapamil nebo diltiazem. P\u0159i p\u0159etrv\u00E1vaj\u00EDc\u00ED angin\u00F3zn\u00ED symptomatologii je v\u00FDhodn\u00E9 k beta-blok\u00E1tor\u016Fm p\u0159idat blok\u00E1tory kalciov\u00FDch kan\u00E1l\u016F ze skupiny dihydropyridin\u016F 2. generace. U hypertonik\u016F s ICHS a systolickou dysfunkc\u00ED lev\u00E9 komory jsou indikov\u00E1ny inhibitory ACE, event. blok\u00E1tory AT1-receptor\u016F pro angiotensin II (AT1-blok\u00E1tory). M\u011Bly by b\u00FDt zva\u017Eov\u00E1ny i u nemocn\u00FDch s ICHS a norm\u00E1ln\u00ED funkc\u00ED lev\u00E9 komory. (Kap Kardiol 2011; 3: 59\u201363)" . . "1"^^ . . . . "Hypertenze zvy\u0161uje riziko kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED a akceleruje rozvoj ateroskler\u00F3zy. Riziko kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED u hypertonik\u016F lze v\u00FDznamn\u011B sn\u00ED\u017Eit \u00FA\u010Dinnou antihypertenzn\u00ED l\u00E9\u010Dbou. V sou\u010Dasn\u00E9 dob\u011B je u pacient\u016F s ischemickou chorobou srde\u010Dn\u00ED (ICHS) doporu\u010Dov\u00E1no dos\u00E1hnout c\u00EDlov\u00FDch hodnot krevn\u00EDho tlaku 130\u2013139/80\u201385 mm Hg. L\u00E9ky volby u hypertenze prov\u00E1zen\u00E9 anginou pectoris a u nemocn\u00FDch po infarktu myokardu jsou beta-blok\u00E1tory. Kardioselektivn\u00ED beta-blok\u00E1tory jsou jednozna\u010Dn\u011B indikov\u00E1ny tak\u00E9 u diabetik\u016F s ICHS. N\u011Bkter\u00E9 beta-blok\u00E1tory (carvedilol, bisoprolol, metoprolol ZOK a nebivolol) zlep\u0161uj\u00ED progn\u00F3zu nemocn\u00FDch s chronick\u00FDm srde\u010Dn\u00EDm selh\u00E1n\u00EDm. Alternativn\u011B lze p\u0159i norm\u00E1ln\u00ED funkci lev\u00E9 komory (zvl\u00E1\u0161t\u011B p\u0159i kontra indikaci nebo intoleranci beta-blok\u00E1tor\u016F) u\u017E\u00EDt verapamil nebo diltiazem. P\u0159i p\u0159etrv\u00E1vaj\u00EDc\u00ED angin\u00F3zn\u00ED symptomatologii je v\u00FDhodn\u00E9 k beta-blok\u00E1tor\u016Fm p\u0159idat blok\u00E1tory kalciov\u00FDch kan\u00E1l\u016F ze skupiny dihydropyridin\u016F 2. generace. U hypertonik\u016F s ICHS a systolickou dysfunkc\u00ED lev\u00E9 komory jsou indikov\u00E1ny inhibitory ACE, event. blok\u00E1tory AT1-receptor\u016F pro angiotensin II (AT1-blok\u00E1tory). M\u011Bly by b\u00FDt zva\u017Eov\u00E1ny i u nemocn\u00FDch s ICHS a norm\u00E1ln\u00ED funkc\u00ED lev\u00E9 komory. (Kap Kardiol 2011; 3: 59\u201363)"@cs . "Hypertension and ischemic heart disease"@en . "[9F8906DF6000]" . "http://www.tribune.cz/clanek/23154-hypertenze-a-ischemicka-choroba-srdecni" . "RIV/00064190:_____/11:#0000285!RIV12-MZ0-00064190" . "C\u00EDfkov\u00E1, Renata" . . . "Kapitoly z kardiologie pro praktick\u00E9 l\u00E9ka\u0159e" . . . "Hypertension and ischemic heart disease"@en . "1803-7542" . "203219" . . . "angina pectoris; myocardial infarction; acute coronary syndrome; target BP; J curve; beta-blockers; calcium channel blockers; ACE inhibitors"@en . "CZ - \u010Cesk\u00E1 republika" .